# Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases

> **NCT06891365** · PHASE1 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Volunteers
- Hepatic Steatosis

## Interventions

- **DRUG:** NNC0581-0001
- **DRUG:** Placebo (NNC0581-0001)

## Key facts

- **NCT ID:** NCT06891365
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2027-10-11
- **Final completion:** 2027-11-15
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891365, "Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06891365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*